| 101 |
Pegylated liposomal doxorubicin in patients with metastatic triple-negative breast cancer: 8-year experience of a single center |
2020 |
| 102 |
Pegylated liposomal doxorubicin in patients with metastatic triple-negative breast cancer: 8-year experience of a single center |
2020 |
| 103 |
Predictive and Prognostic Factors for the Outcome of the Patients Receiving Pegylated Liposomal Doxorubicin for Advanced Breast Cancer |
2020 |
| 104 |
Predictive and Prognostic Factors for the Outcome of the Patients Receiving Pegylated Liposomal Doxorubicin for Advanced Breast Cancer |
2020 |
| 105 |
Predictive and Prognostic Factors for the Outcome of the Patients Receiving Pegylated Liposomal Doxorubicin for Advanced Breast Cancer |
2020 |
| 106 |
Right and Left Colon Cancer: Clinico-Pathological Features and Treatment Results (South Egypt
Cancer Institute Experience) |
2020 |
| 107 |
Right and Left Colon Cancer: Clinico-Pathological Features and Treatment Results (South Egypt
Cancer Institute Experience) |
2020 |
| 108 |
Right and Left Colon Cancer: Clinico-Pathological Features and Treatment Results (South Egypt
Cancer Institute Experience) |
2020 |
| 109 |
The diagnostic efficacy of tailored multiparametric breast MRI in indeterminate mammographic lesions: A single tertiary oncology center |
2020 |
| 110 |
The diagnostic efficacy of tailored multiparametric breast MRI in indeterminate mammographic lesions: A single tertiary oncology center |
2020 |